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Sustainable Super-Sprinkle: 
Powdered Local Foods
Stacia Nordin
I appreciate Zlotkin and colleagues’ years of work on the 
Sprinkle product, and it sounds like the product is much 
improved from the pill form of micronutrient treatments 
[1]. I’m not at all opposed to Sprinkle-type products or other 
nutrient pills for treatment (or in other special situations), 
but as ten years of international work experience on food 
and nutrition security issues has shown me, few programmes 
are supporting local solutions to problems. Once again, a 
message is being sent that nutrition comes from a pill or 
packet, made by a foreigner, and requires money.
In the case of Sprinkles, the product could support local 
solutions by including a message on each sachet about the 
importance of eating a wide variety of local foods—or a 
picture of local fruits, vegetables, and legumes. Instead of just 
sprinkling a packet onto a bulky carbohydrate food, use the 
Sprinkles as treatment along with instruction about planting 
and eating less of that bulky carbohydrate in the ﬁ  rst place. 
Even better would be to take all that research, time, energy, 
and money to teach people (or local manufacturers) how 
to make their own Sprinkles from local nuts, fruits, greens, 
oilseeds, insects, ﬁ  sh, and the like. 
The results could be just as immediate and dramatic, 
but with an impact that could last for generations to come. 
The organisations that support this type of permanent 
intervention could be mentioned during every teaching 
session along with big banners and ﬂ  yers that announce 
them as the inventors and/or supporters. Just imagine a nice 
sprinkle powder that everyone can have on hand to improve 
their own nutrition without relying on a packet from an 
outside source that is manufactured with machines and jetted 
in with thousands of litres of petrol (or trucked across the 
country, if it is made in country).
I’m sure that pre-packaged, imported products have their 
place in wars, tsunamis, a few cities, and other disasters, but 
for the majority of the 750 million children in the developing 
world, their own indigenous foods would have just as much 
effect, with a longer-term impact on the society’s nutritional 
health.
I saw Zlotkin’s presentation on Sprinkles at the 
International Congress of Dietetics conference in Chicago, 
Illinois, in 2004, and he did include a sentence about 
diversifying diets as part of the whole project, but it was 
strongly overshadowed by discussion of bringing in external 
resources and experts. When I asked him about using the 
same resources that went into developing, manufacturing, 
and transporting Sprinkles to create a local sprinkle product 
with an emphasis on local diversiﬁ  ed diets, he immediately 
responded that it wouldn’t work.
How do we know, if no one really puts the effort into it at 
the level that products like Sprinkles get?
I’ve posted this message to several food and nutrition 
listservs and magazines, and I am now beginning to learn of 
some small projects working towards local sprinkle products. 
Zlotkin and team could assist these projects to research the 
work and scale it up to other countries with other local foods.  
Stacia Nordin
Lilongwe, Malawi
E-mail: nordin@eomw.net
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Authors’ Reply: Sprinkles as a Home Fortiﬁ  cation 
Strategy to Improve the Quality of Complementary 
Foods
We are writing in response to the letter by Stacia Nordin [1]. 
Independent of where a child is born in the world, the most 
appropriate feeding regimen is breast milk until six months of 
age, followed by a weaning or complementary food [2]. It is 
known that breast milk provides all the essential nutrients for 
a growing infant, except for vitamin D. It is also known that 
complementary foods should contribute to providing all of 
the essential nutrients when breast milk is no longer the sole 
source of nutrition after the ﬁ  rst few months of life. However, 
as early as 1930, it was realized that typical complementary 
foods were generally poor sources of micronutrients 
(minerals and vitamins) and were often not sufﬁ  cient to meet 
the micronutrient needs of growing children. For example, 
per 100 g, rice-based complementary foods contain about 1 
mg of iron, and wheat-based complementary foods contain 
about 0.8 mg of iron [3]. Even a meat-based complementary 
food, such as commercial “toddler beef stew”, contains only 
1.2 mg of iron in each 170-g jar. Since the recommended 
dietary allowance for iron is 11 mg/day (for ages 7–12 
months) [4], clearly a rice- or wheat-based complementary 
food, or even a dilute meat-based stew, would not provide an 
adequate amount of iron for a growing infant. 
Pablum, the ﬁ  rst fortiﬁ  ed baby food, was invented at the 
Hospital for Sick Children in Toronto, Canada, in the 1930s 
[5]. Subsequently, by the early 1960s in North America, all 
commercially manufactured infant cereals were fortiﬁ  ed with 
iron. Today, the major source of iron in the diet of a North 
American child is fortiﬁ  ed commercial infant cereals. And, 
indeed, the low rates of iron-deﬁ  ciency anaemia in Canada 
and the United States are thought to be partly a result of the 
widespread use of commercially available iron-fortiﬁ  ed cereals 
[6]. 
Another good example of a fortiﬁ  ed food for young 
children in North America is ﬂ  uid milk products, which are 
fortiﬁ  ed with vitamin D in order to prevent the development 
of rickets. It is currently well accepted among nutritionists 
and pediatricians that most young children in North America 
depend on fortiﬁ  ed foods to meet their micronutrient needs. 
In most developing countries, access to commercially 
processed baby foods (fortiﬁ  ed with iron) is very limited PLoS Medicine  |  www.plosmedicine.org 0685
mainly because of their high cost and limited availability 
[7]. It is noteworthy that recent research has demonstrated 
that even if dietary diversiﬁ  cation and modiﬁ  cation (such as 
soaking, fermentation, and germination) strategies are used 
at the household level, they may not be sufﬁ  cient to overcome 
the deﬁ  cits in iron and other micronutrients [3]. As a result, 
other options need to be considered for young children 
living in developing and poor countries to ensure that all of 
their nutrient requirements are met [8]. The use of Sprinkles 
is one such option [9,10]. One of the greatest advantages 
of the Sprinkles concept is its emphasis on complementary 
food consumption because Sprinkles have to be mixed 
with food. When educating caregivers about anaemia and 
the use of Sprinkles, healthy weaning practices can be 
concurrently promoted to ensure the timely introduction 
of complementary foods at six months of age in addition to 
continued breast feeding (as recommended by the World 
Health Organization) [2]. This is an important beneﬁ  t, as 
it is well known that in many developing countries poor 
weaning practices are common [3]. As a home fortiﬁ  cant, 
Sprinkles ensure that the food eaten contains adequate 
amounts of essential micronutrients. Indeed, Sprinkles are 
meant to improve the nutritional value of homemade baby 
foods, which are otherwise poor in micronutrient content. 
Sprinkles can enrich foods not only with iron but also with 
other essential micronutrients such as zinc, folic acid, and 
vitamins A and C.  In addition, since Sprinkles can be easily 
mixed with any homemade semisolid foods, their use does 
not require any change in food practices; thus, they can be 
easily accepted in diverse cultural settings. 
With anaemia rates as high as 80% in young children in 
some developing countries, current food-based strategies 
alone are clearly not effective. All children should have the 
right to eat foods that meet their nutritional needs. The 
use of Sprinkles is one way to help these children meet 
their nutrient requirements. Unfortunately, a food-based 
strategy alone, using locally available unfortiﬁ  ed foods, in 
most circumstances, is simply inadequate and may further 
predispose a growing child to various micronutrient 
deﬁ  ciencies [8].  
Stanley H. Zlotkin (Stanley.Zlotkin@sickkids.ca)
Hospital for Sick Children and University of Toronto 
Toronto, Ontario, Canada 
Claudia Schauer
Anna Christoﬁ  des 
Waseem Sharieff
Mélody C. Tondeur 
S. M. Ziauddin Hyder
Hospital for Sick Children
Toronto, Ontario, Canada 
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Bold Suggestion by Smith
David Cohen
Richard Smith’s key suggestion [1] is that medical journals 
“should stop publishing trials” and concentrate on “critically 
evaluating them.” This bold and radical suggestion deserves 
wide debate. It’s obvious that many medical journals are 
losing relevance as vehicles for scientiﬁ  c information, but 
it’s unclear what will save them. Even as journals strive to 
better enforce their conﬂ  icts-of-interest disclosure rules, 
drug companies will strive to ﬁ  nd or create other publication 
outlets that can communicate to physicians precisely what 
advertisers wish to communicate. In sum, an unanticipated 
effect of purging clinical trial reports from medical journals 
might be an even larger proliferation of frank advertising 
outlets and messages that might more effectively catch 
doctors’ attentions.  
David Cohen
Florida International University
Miami, Florida, United States of America
E-mail: david.cohen@ﬁ  u.edu
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Medical Journals, Academia, and 
Industry-Sponsored Clinical Trials
Valeria Frighi
Sadly, I fully agree with Richard Smith’s opinion [1] that 
many medical journals have become marketing ofﬁ  ces of 
pharmaceutical companies. Even worse is that few people 
seem to realize this, and there are many respectable 
academics who would wholeheartedly dispute these 
views. The “psychology of gift” operates in every social 
environment, being so pervasive because it is based on the 
profoundly human and universal norm of reciprocity [2,3]. 
In academia and medical publishing it produces great 
returns to the pharmaceutical industry via clinical scientists 
who are not dishonest but in a state of denial about their 
motivations, as Jerome Kassirer, former editor of the New 
England Journal of Medicine, describes very clearly in his 
recent book [4]. What is happening is also extremely serious 
because the tainted trials we are offered can make evidence-
based medicine a pointless enterprise. Again, something not 
widely appreciated. 
I think Smith’s suggestions that there should be more 
public funding for clinical trials and that journals should 
critique rather than publish the results of the trials are very 
interesting. However, how are we going to get publicly, and 
adequately, funded trials given the current ﬁ  nancial climate? 
A practical alternative to Smith’s suggestion is to play 
one pharmaceutical company against the other in head-to-
head trials, an approach that can help retain independence 
and that has been used to this purpose before. Another 
strategy would be for either the regulatory authorities or the 
academic review boards to demand of the pharmaceutical 
companies that whenever a new drug is tested in a phase III 
trial, it should always be done not only against placebo but 
also against the drug that the condition is generally treated 
with. This active comparator must be used at the appropriate 
dose, namely neither too low nor too high (in order to avoid 
the tested drug spuriously seeming more effective or safe). 
Moreover, any new licence should be accompanied by a 
legal requirement for a stringent system of post-marketing 
surveillance, to be run by the drug company but overviewed 
by the regulatory authority. 
These strategies could possibly help produce results that 
are more reliable from a scientiﬁ  c point of view, help reduce 
the number of expensive but not innovative “me too” drugs, 
and help protect patients’ safety more efﬁ  ciently. 
Lastly, I hope Richard Smith will go straight into the 
lion’s den and send his thoughts not only to the similarly 
minded editors and readers of PLoS Medicine but to some of 
the journals who are the most culpable of the policy he is 
exposing.  
Valeria Frighi
Churchill Hospital
Oxford, United Kingdom
E-mail: valeria.frighi@doctors.org.uk
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Might Banning Trial Publication 
Do More Harm Than Good?
David Sackett
Smithereens are better than no Smith at all. It was grand to 
see Richard Smith in full ﬂ  ight again [1], a raptor this time, 
relegating the randomized controlled trials he previously 
championed in the BMJ to the ether, to be replaced 
by printed “commentaries.” In doing so, he laid three 
problematic eggs. First, he shoved systematic reviews and 
meta-analyses, surely the least biased summaries of efﬁ  cacy, 
out of the nest before he took off. Second, the canaries who 
write commentaries often live in gilded cages provided by 
the drug industry and printing their pronouncements would 
make matters worse. Finally, the ﬂ  edglings who conduct 
nondrug health-care trials, especially in low- and middle-
income countries, shouldn’t have their careers stunted by not 
being able to publish their work in print journals.  
David Sackett
Harlot
Irish Lake, Ontario, Canada
E-mail: sackett@bmts.com
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Little Fish Are Less Likely to Take 
the Bait
Harvey Marcovitch
One solution for fair-minded doctors not mentioned by 
Smith [1] might be to keep away from major high-impact 
July 2005  |  Volume 2  |  Issue 7  |  e218  |  e220  |  e221PLoS Medicine  |  www.plosmedicine.org 0687
journals and subscribe instead to those with a lower proﬁ  le 
but that serve their specialty. I analysed all original papers 
published in the last 12 issues of Archives of Disease in 
Childhood. Of 198 such papers, there were seven (3.5%) 
manufacturer-funded studies dealing with drugs, vaccines, 
or infant foods. Another ten papers (5%) dealt with drugs 
or vaccines, including three reports of adverse events, 
but were not funded by industry. The funding of one was 
obscure. This pristine record was somewhat spoiled by a 
sponsored supplement, but clearly labelled as such, about a 
particular medication. It provoked an angry correspondence 
on the subscribers’ message board of one of the co-
publishers. It seems that at least paediatrics, a far-away 
specialty of which Smith may know little, treads a careful 
path.  
Harvey Marcovitch
BMJ Publishing Group
London, United Kingdom
E-mail: h.marcovitch@btinternet.com
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Focus on the Funding and Production 
of Evidence Rather Than Its Publication
Trevor Sheldon
Richard Smith has correctly highlighted the potential 
distortion of the evidence base caused by the publication of 
commercially sponsored trials [1]. However, his proposed 
solution could do with more thought. 
First, let us be clear that the problem is possibly much 
wider than drug-company trials. There is the risk of 
systematic bias in reports of any research funded by a body 
that has an interest in the results. This “sponsor-induced 
bias” has been well documented in the area of tobacco-
company-funded research on the effects of direct and 
indirect smoking [2]. In addition, governments, charities 
with an interest in a disease, and other bodies may also 
help to ensure that the results of research they sponsor 
(including trials) or the reporting of research favour 
one particular outcome. Lastly, individuals who carry out 
research, even if not funded by an interest group, may also 
bring prejudices to the table that inﬂ  uence the results and 
the published report. In other words, the tendency to bias 
is omnipresent. The issue of commercially funded trials is 
simply one of the degree and inﬂ  uence that trials have on 
clinical practice and health-care spending.
Following Smith’s thinking to its logical conclusion, 
we would not publish any research but simply critiques. 
Smith proposes that instead of publishing trials, journals 
should concentrate on critically describing them. If he 
is not conﬁ  dent that the current system of peer review is 
sufﬁ  ciently robust to identify weaknesses, why should he 
be any more conﬁ  dent in the critiquing process (which is 
a form of peer review)? Journal peer review is often ad hoc 
(especially when my work is rejected) and is in desperate 
need of professionalizing, but I suspect along with Smith 
that this is not sufﬁ  cient protection. Surely the way to 
deal with the systematic risk of bias is a reform not in the 
publication but in the production of evidence, which in 
turn reﬂ  ects the way it is funded, conducted, analysed, and 
reported. 
My alternative solution in the case of trials is as follows. 
Companies (or indeed any body with a particular interest) 
should not be allowed to directly fund a clinical trial and no 
journal should publish a company-sponsored trial. Instead 
industry should pay a public or independent trials body, 
staffed by the best methodologists around and possibly 
established on an international scale. This international 
infrastructure should be publicly funded so that its staff do 
not feel dependent on industry business for security. The 
body, in conjunction with clinical experts from around the 
world, should conduct the study, ensuring that the questions 
are in the public’s interest and fair (consumers would have an 
important role to play here). 
This infrastructure would ensure that the research was 
of the highest standard and reported accurately. Once the 
funding had been agreed on, there would be a compulsion 
to register the trial and to publish no matter what the 
results. This body would also have the ability to carry out 
or commission economic modelling (which is even more 
susceptible than trials to sponsor-induced bias) [3]. The 
resulting data would be held in a publicly accessible data 
archive. We should have an international agreement that no 
phase III trials would be permitted other than through this 
route. While still a rather bureaucratic response, it would 
ensure that the evidence base was less contaminated. Drug 
companies might even ﬁ  nd that such a social solution results 
in trials being cheaper and easier to run.  
Trevor Sheldon
University of York
York, United Kingdom
E-mail: tas5@york.ac.uk
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Bitter Pills and Puffed Trials
Stephen Senn
I agree with Richard Smith [1] that something needs to 
be done about the reporting of pharmaceutical industry 
trials. Like him, I believe that the solution should include 
compulsory publication on the Internet of trials [2]. 
However, I disagree that the problem has its origin with the 
pharmaceutical industry; it is inherent to medical publication. 
Of his eight ways of massaging data, the last ﬁ  ve are dealt 
with by the International Conference on Harmonisation 
guidelines covering statistical principles for clinical trials 
(ICH E9)[3] that require prespeciﬁ  cation of analyses. It is 
not possible to claim noninferiority on the basis of failure 
to prove a difference, and a paper describing appropriate 
approaches to equivalence trials that Richard Smith thought 
worth publishing in the BMJ [4] was doing no more than 
explaining what was common practice within the industry. 
The ﬁ  rst three points are less easily policed, although choice 
of control group is taken extremely seriously, and, indeed, 
there is an appropriately entitled guideline [5] that covers 
this.
The problems are inherent to publication not drug 
regulation. An instance: the New England Journal of Medicine 
published in January 2002 a paper claiming that voriconazole 
is a suitable alternative to amphotericin B preparations for 
empirical antifungal therapy in patients with neutropenia 
and persistent fever [6]. However, a letter to the editor in 
the same issue of that journal from scientists based at the 
United States Food and Drug Administration [7] pointed 
out that the analysis presented was not what was prespeciﬁ  ed 
in the protocol and that not only had voriconazole failed to 
demonstrate noninferiority, but it was actually statistically 
signiﬁ  cantly inferior to amphotericin B. Surely, responsibility 
for this discrepancy cannot be laid at the door of the Food 
and Drug Administration, nor can it be blamed on Pﬁ  zer. 
Rather, the authors and the New England Journal of Medicine 
owe readers some sort of explanation. 
Do the editors agree with Richard Smith (and me) that 
a published paper, whatever else it covers, should always 
identify the results of prespeciﬁ  ed analysis, and if so, how do 
they check that this is so? 
Thus, I agree with Richard Smith that much is wrong 
with the publication of clinical trials sponsored by the 
pharmaceutical industry. I disagree that it is a particular 
problem for industry trials. It is the publication process that 
is in need of reform, and in particular we need to scrutinize 
carefully the motives of authors in publishing and the 
standards that editors apply in deciding what gets published.  
Stephen Senn
University of Glasgow
Glasgow, United Kingdom
E-mail: stephen@stats.gla.ac.uk
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Editors’ Reply
Steven Senn [1] raises several very important points about the 
publication of trials. In an attempt to improve transparency 
of reporting, we require authors to submit their protocol 
along with the trial so that it is available for reviewers and 
editors to compare with the journal article, and we encourage 
the protocol to be published with the trial so that readers 
can check these results for themselves. One problem in trial 
reporting is the relatively unstructured nature of trial reports 
in medical journals compared with, for example, Trial Bank 
(http:⁄⁄rctbank.ucsf.edu/). We are currently considering how 
we report trials at PLoS; a much more structured and, hence, 
more transparent report may make it much harder to hide 
results (or the lack of them).  
Virginia Barbour, Barbara Cohen, Gavin Yamey
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A Further Response to Shah Ebrahim
Michael Makover
Shah Ebrahim says, in his answer to my statement in our 
debate [1], that plaque is so common that it makes sense 
to treat only those likely to have an acute event in the near 
future. Not everyone has a heart attack but everyone ages, nor 
can we be sure who will be lucky as they age and who will not. 
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Anyone with a low-density lipoprotein level above 70 mg/dl 
is at risk [2]. Narrowing of arteries must certainly contribute 
to health decline in aging. He says that most plaque is stable 
and does not rupture. The half-million people who have a 
heart attack and the hundreds of thousands of individuals 
who have a stroke in the United States alone each year would 
disagree. Waiting decades more for further studies will not 
help all those now succumbing to the disease, as long as all 
the components have already been well vetted, as they have 
been. Ebrahim’s statement that “most [plaques] are stable 
and unlikely to rupture” is based on his own study published 
in Stroke [3], but the paper has no data relating to how many 
patients found to have increased intima-media wall thickness 
(IMT) or plaque actually had heart attacks or strokes. It did 
ﬁ  nd that intimal-wall changes were highly associated with 
ischemic heart disease.
It is correct that risk factors can predict heart disease 
and stroke to some degree, though I have many patients 
for whom that approach fails while IMT detects the risk 
otherwise missed. However, risk factor analysis is not 
enough. Changes in smoking, diet, weight, blood pressure, 
and such are all targets for treatment, but how do doctors 
know whether they have controlled them adequately? If 
IMT increases, more control is required. If IMT stabilizes or 
reverses a little, then it means that control is at goal. Family 
history of premature coronary artery disease is a major but 
underused risk factor. The causative factors have not yet been 
elucidated by research, so we do not know what the goals 
are. However, IMT provides a highly satisfactory parameter 
by which to judge the effectiveness of treatment in familial 
coronary artery disease: IMT stabilization and reversal are 
good, whereas progression is bad and requires more intensive 
measures. 
Epidemiology and public-health planning correctly look at 
policies to apply to large populations. However, the practice 
of medicine is patient by patient, accomplished in the face-
to-face doctor–patient relationship. Policy can be useful 
as a resource, but each patient should have the maximum 
individualized care and access that a doctor can provide. 
Patients should be able to make their own informed choices 
and not be dictated to by policies meant for masses. Shouldn’t 
everyone with increased IMT at least be informed of the 
options available to limit it rather than waiting until acute 
events or advanced narrowing occur? It would be best to start 
a healthy lifestyle from birth, but fortunately by adulthood 
there is still time to make an enormous difference in practical 
terms if we take action at the stage when intimal widening is 
detectable with the highly sensitive ultrasound described in 
my original viewpoint [1].  
Michael Makover
New York University School of Medicine
New York, New York, United States of America
E-mail: mmakover@optonline.net
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Author’s Reply
In response to Michael Makover’s comments [1], the 
important point at issue here is evidence—and not whether 
there is room for both population approaches and high-risk 
approaches. We can certainly identify plaques using carotid 
ultrasound. We can use risk factor scoring schemes to identify 
those at high risk of suffering a cardiovascular event. We can 
give patients a range of drugs that have been shown in trials 
to reduce risk of these events. However, the relevant evidence 
from randomised controlled trials of risk factor screening 
(using either scores or carotid ultrasound) and intervention 
is simply not available. So what do we do—ignore the lack of 
evidence?  Or do we get on with organising the trials?  
Shah Ebrahim
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Applause to PLoS Medicine
for Initiating Student Forum
C. Jairaj Kumar, Abhizith Deoker
We congratulate and acknowledge PLoS Medicine for initiating 
a students’ forum [1] and for its efforts to encourage 
students’ participation across the globe. There is really a need 
for medical students, especially from the developing world, to 
be actively conducting research, reading journals, publishing 
papers, and staying in touch with current developments in the 
ﬁ  eld of medicine. Many developing countries lack a national-
level student medical journal for students to exchange their 
views and ideas, which thereby paciﬁ  es their thinking and 
makes them hypnotic to issues such as the inﬂ  uence of drug 
companies and the neglected health problems of poorer 
countries. 
It will be really motivating for students from developing 
countries to actively take part in debate through the Student 
Forum of PLoS Medicine, which is composed of articles 
selected by student representatives across the world. The 
unique integration of student associations with PLoS Medicine, 
and the journal’s policy of not publishing advertisements for 
drugs or medical devices, will also enlighten students about 
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the inﬂ  uence of drug companies in medical practice and 
enable students to realize their priorities in poorer countries 
for the future. Thereby, students may focus their attention 
on becoming professionals in developing new strategies to 
combat killer infectious diseases like malaria and tuberculosis, 
and malnutrition—such as vitamin deﬁ  ciencies among 
children and iron deﬁ  ciency among pregnant women—that 
are dreaded and very common in poorer countries.  
C. Jairaj Kumar (E-mail: jairaj81in@yahoo.co.in)
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